<DOC>
	<DOCNO>NCT00493246</DOCNO>
	<brief_summary>We study find happens acetaminophen body give child vein . Children 's body may handle drug differently adult . Understanding long drug stay body drug change metabolize body ( call pharmacokinetics ) important step learn best dose acetaminophen child . We also interest learn safety medication give child .</brief_summary>
	<brief_title>Safety Pharmacokinetic ( PK ) Study Intravenous ( IV ) Acetaminophen Administration Pediatric Inpatients</brief_title>
	<detailed_description>A Prospective , Multi-Center , Randomized , Open-Label , Single Repeated Dose , 48 Hour Study , Intravenous Acetaminophen Pediatric Inpatients Determine Pharmacokinetics ( PK ) Safety Acute Pain Fever</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>To eligible entry Study , Subjects must meet Subjects ' Parent Guardian must meet , agree confirm follow criterion : 1 . Provide write Informed Consent/Assent prior participation Study 2 . Age stratum : Fullterm Neonates ( ≤ 28 day old minimum post conception age 37 week birth ) Infants [ 29 day &lt; 2 year ( yr ) old ] 29 day &lt; 6 month 6 &lt; 12 month 12 &lt; 24 month ) Children ( 2 yrs &lt; 12 yrs old ) Adolescents ( 12 yrs ≤16 yr old ) 3 . Inpatient status : currently inpatients admission schedule soon become inpatient ( e.g. , elective surgery ) 4 . Diagnosis : require require analgesic treatment acute pain antipyretic treatment fever 5 . IV access : need IV access duration Study either due nothing mouth ( NPO ) status due Investigator 's assessment oral treatment optimal ( example , severe nausea vomit ) 6 . The Subject 's Parent/Guardian must ability read understand Study procedures ability communicate meaningfully Study Investigator staff 7 . Be free physical , mental , medical condition , opinion Investigator complete screen assessment , make Study participation inadvisable 8 . If female child bear potential , negative pregnancy test Exclusion Criteria ( Screening ) A Subject NOT eligible entry ANY follow criterion meet : 1 . Is able comply plasma sampling requirement Study 2 . Has know suspect hypersensitivity acetaminophen inactive excipients IV Acetaminophen . 3 . Has take acetaminophencontaining product 12 hour prior follow 48 hour prior randomization Study : probenecid , disulfiram , isoniazide , St. John 's wort , skullcap , chaparral , comfrey , germander , jin bu huan , kava , pennyroyal , valerian 4 . Has significant medical condition opinion Investigator contraindicate participation Study 5 . Has impair liver function , evidence clinically significant liver disease , condition may suggest potential increased susceptibility hepatic toxicity IV APAP exposure . For criterion , total bilirubin great 1.5 time upper limit normal ( ULN ) age Alanine aminotransferase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) Aspartate transaminase ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) great 2.5 time ULN age deem evidence clinically significant ( Common Terminology Criteria Adverse Events [ CTCAE ] Grade 2 ) liver dysfunction disease . 6 . Has significantly impair renal function know significant renal disease , evidence estimate glomerular filtration rate ( use Schwartz formula ) calculate less 1/3rd normal applicable age strata 7 . Has participate another interventional clinical Study ( investigational market product ) within 30 day plan Study randomization date</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>